Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolomic study of bevacizumab treatment in lung cancer
ChiCTR-OCC-14004438Phase 4Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of bevacizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Small molecules and Lipids. Started Sep 2012; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-OCC-14004438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OCC-14004438.